Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
Shoulder Innovations, Inc. CEO and Executive Chairman Robert Joseph Ball reported exercising stock options for common stock on February 6, 2026. He acquired 10,000 shares at $2.4804 per share and 2,062 shares at $2.0988 per share through option exercises coded “M.”
After these transactions, Ball directly beneficially owned 276,666 shares of common stock. His option holdings included 319,756 and 181,376 stock options remaining after the exercises. Footnotes note that his holdings include over 140,000 shares previously received without consideration as in‑kind distributions from several investment funds.
Shoulder Innovations, Inc. granted Chief Financial Officer Jeffrey S. Points a stock option on January 30, 2026. The option covers 126,357 shares of common stock at an exercise price of $14.16 per share.
The option is held directly and vests in four equal annual installments, with one-fourth of the underlying shares vesting on March 1 each year, beginning March 1, 2027. After this grant, Points beneficially owns 126,357 stock options tied to common shares.
Shoulder Innovations, Inc. reported that officer David Lawrence Blue received a grant of stock options on January 30, 2026. The award covers 88,450 options for common stock at an exercise price of $14.16 per share, all held as a direct ownership position.
The options vest in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning March 1, 2027, until fully vested. After this grant, Blue beneficially owns 88,450 derivative securities in the form of these stock options.
Shoulder Innovations, Inc. granted stock options to its CEO and Executive Chairman, Robert Joseph Ball. On January 30, 2026, he received a stock option covering 265,351 shares of common stock at an exercise price of $14.16 per share.
The option was granted directly to him and is scheduled to vest in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning on March 1, 2027, which spreads the potential ownership benefit over several years.
Shoulder Innovations, Inc. disclosed a new stock option grant to Chief Operating Officer and director Matthew Fraser Ahearn. On January 30, 2026, he received an option covering 88,450 shares of common stock at an exercise price of $14.16 per share.
According to the vesting terms, the option vests in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning on March 1, 2027, aligning the award with multi-year executive retention and performance incentives.
Shoulder Innovations, Inc. Chief Financial Officer Jeffrey S. Points reported acquiring common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,076 shares of common stock at a purchase price of $12.16 per share, which the plan set at 85% of the closing price of the stock on that date. Following this transaction, he beneficially owned 55,521 common shares directly, and an additional 50 shares indirectly held by his son.
Shoulder Innovations, Inc. officer David Lawrence Blue reported buying common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,041 shares of common stock at $12.16 per share, a price set at 85% of the closing price that day under the ESPP rules. After this transaction, he beneficially owned 139,372 shares, held directly. Blue serves as the company’s Chief Customer Experience Officer, and the filing notes that this is a voluntary report of the ESPP purchase.
Shoulder Innovations, Inc. CEO & Executive Chairman Robert Joseph Ball reported acquiring additional common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,661 shares of common stock at a purchase price of $12.16 per share, which the plan set at 85% of the closing price of the company’s common stock on that date. Following this ESPP purchase, Ball beneficially owned 120,118 shares of Shoulder Innovations common stock held directly.
Shoulder Innovations, Inc. director and Chief Operating Officer Matthew Fraser Ahearn reported acquiring common stock through the company’s 2025 Employee Stock Purchase Plan (ESPP). On December 31, 2025, he acquired 477 shares of common stock at a purchase price of $12.16 per share, which the ESPP sets at 85% of the closing price of the stock on that date. Following this transaction, he beneficially owned 215,856 shares of Shoulder Innovations common stock in direct ownership.
Shoulder Innovations, Inc. Chief Financial Officer Jeffrey S. Points reported acquiring additional company stock. On 12/11/2025 he acquired 995 common shares at $14.65 per share, and on 12/12/2025 he acquired 1,005 shares at $14.98. Following these transactions, he directly owned 54,445 common shares. He also reported indirect beneficial ownership of 50 shares held by his son.